3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
172
Breast Neoplasms
24
Neoplasms
13
Leiomyoma
11
Polycystic Ovary Syndrome
5
Prostate Adenocarcinoma
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Rare Diseases
2
Myofibroma
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Breast Neoplasms, Male
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urogenital Neoplasms
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Salivary Gland Neoplasm Duct
1
Respiratory Tract Diseases
1
Recurrence
1
Puberty, Precocious
1
Interventions
Fulvestrant
10
Everolimus
6
Cetuximab
6
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hereditary Sensory and Autonomic Neuropathies
×
Leuprolide
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts